Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer-Reference-Cited by-同舟云学术

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer

Published:2022-02-21 Issue:2 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ngoi Natalie YL¹,Syn Nicholas LX¹²³,Goh Robby M¹,Goh Boon Cher¹,Huang Ruby Yun-Ju⁴,Soon Yu Yang⁵,James Elizabeth⁶,Cook Adrian⁶,Clamp Andrew⁷,Tan David SP¹³⁴

Affiliation:

1. Department of Haematology-Oncology; National University Cancer Institute; Singapore Singapore

2. Department of Surgery; University Surgical Cluster, National University Health System; Singapore Singapore

3. Yong Loo Lin School of Medicine; National University of Singapore; Singapore Singapore

4. Cancer Science Institute of Singapore; National University of Singapore; Singapore Singapore

5. Department of Radiation Oncology; National University Cancer Institute; Singapore Singapore

6. Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology; University College London; London UK

7. Department of Medical Oncology; The Christie NHS Foundation Trust and University of Manchester; Manchester UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference84 articles.

1. Chan J Brady M Penson R Monk B Boente M Walker J Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712) Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology

2. Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712);Chan;International Journal of Gynecological Cancer,2013

3. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer;Chan;New England Journal of Medicine,2016

4. Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262;Chan;Gynecologic Oncology,2017

5. Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study;Blagden;International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods;World Journal of Methodology;2024-06-20

2. Advances in the role of GPX3 in ovarian cancer (Review);International Journal of Oncology;2024-01-30

3. Identifying Explainable Machine Learning Models and a Novel SFRP2+ Fibroblast Signature as Predictors for Precision Medicine in Ovarian Cancer;International Journal of Molecular Sciences;2023-11-29

4. Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer;Journal of International Medical Research;2023-09

5. Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity;International Journal of Molecular Sciences;2022-12-09